As the example shows p53, which is simply testing the various forms of chemotherapy resistance in practice. To date, no chemosensitivity testing in routine proved to cancer patients.
This is particularly true for the products of many commercial vendors that offer patients an appropriate diagnosis for a fee. Here are often advertised with the supposedly rapid implementation of the latest research results - whether the tests are worth the cost, most insurance companies do not reimburse the remains questionable.
To assess whether chemotherapy is likely to contribute or not presently covered by the data from clinical trials to be more reliable.
The importance of individual assessment of tumor biology and the testing of genetic characteristics of a tumor before treatment started, but changes: New technical solutions make it increasingly possible to test many properties of tumor cells within a short time, yet cost-effective. Has such a test to assess its usefulness of prognostic factors were shown once, it will be included in the framework of recommendations and medical guidelines, patients must then no longer have to worry about it that it is conducted, or even pay for it themselves.
Beginning to a patient develops a resistance to emerge and walks his illness persists despite chemotherapy, may, depending on the situation, bring the bill to another agent but still successful. In the future, a new generation of drugs to alleviate the problem of resistance development, which is addressed more specifically than cytotoxic against tumor cells.
More on the new molecular biological methods of cancer diagnosis and the ensuing "Targeted Therapies read", A fact sheet provides concise information about downloading and printing.
Posting Komentar